there were no significant differences in OS according to age, serum albumin, hemoglobin, sex, white blood cell count, or serum soluble CD30 (≥ or <285.6 ng/mL).
IDO was expressed to varying degrees by histiocytes, dendritic cells, and some endothelial cells, but not by HL tumor cells themselves. In addition, they reported that histologically determined high IDO expression was associated with inferior survival in HL patients. 16 Although they reported these important observations, details of Trp catabolism in HL have not yet been fully explored. Therefore, the aim of the present study was to determine the clinical significance of Trp catabolism in HL patients.
| MATERIALS AND METHODS

| Patients and control subjects
This study included 52 previously untreated HL patients. Fifty healthy volunteers participated as control subjects, and their samples were anonymized. All donors provided written informed consent at blood sampling according to the Declaration of Helsinki, and the present study was approved by the Institutional Ethics Committees of Nagoya City University Graduate School of Medical Sciences (Nagoya, Japan), and the National Hospital Organization Kyushu
Cancer Center (Fukuoka, Japan). Diagnoses and assignment of histological subtypes of HL were made according to the WHO criteria for classification of tumors of hematopoietic and lymphoid tissues. 1, 3 The clinical characteristics of the HL patients analyzed in this study comprised histological subtype, serum soluble CD30 (sCD30) level, and the seven components of the international prognostic score 
| Statistical analysis
Correlations between two variables were assessed using Spearman's rank correlation coefficient (Rs). Differences between two groups were examined with the Mann-Whitney U-test or Fisher's exact test.
The probability of progression-free survival (PFS) and overall survival (OS) was estimated by the Kaplan-Meier method, and both survival times were compared using the log-rank test. 3.4 | Progression-free survival in HL patients according to serum Kyn and Trp levels, Kyn/Trp ratio, and serum sCD30 levels
The 5-year PFS of HL patients in this study was 79.2% (95% confidence interval, 67.0%-91.4%) ( Figure 1A ). Cut-off values for serum Kyn, Trp, and the Kyn/Trp ratio for PFS were set at 1.30 lmol/L, 57.1 lmol/L, and 20.49, respectively (Table S1 ). No significant differences between patients with high or low serum Kyn were seen (5-year PFS 61.4% vs 89.5%; P = .054) ( Figure 1B ), or between those with a high or low serum Trp (84.6% vs 69.9%; P = .050) (Figure 1C) . However, PFS was significantly shorter in patients with a high serum Kyn/Trp ratio than in those with a low ratio (61.7% vs 92.1%; P = .017) ( Figure 1D ).
In the present study, the cut-off value for serum sCD30 for PFS was set at 285.6 ng/mL (Table S2 ). There was no significant difference in the PFS of patients with a high or low serum sCD30 level (5-year PFS 55.0% vs 87.3%; P = .062) (Figure 2A ).
3.5 | Overall survival of HL patients according to serum Kyn and Trp levels, Kyn/Trp ratio, and serum sCD30 levels
The 5-year OS of HL patients is shown in Figure 1E and was 88.6%
(95% confidence interval, 77.4%-99.8%). In the present study, the cut-off values for serum Kyn and Trp, and the Kyn/Trp ratio for OS analysis were set at 1.83 lmol/L, 57.1 lmol/L, and 38.16, respectively (Table S3 ). There were no significant differences in the OS between patients with a high or low serum Kyn level (5-year OS 75.0% vs 89.9%; P = .204) ( Figure 1F ), but OS was significantly shorter in patients with a low serum Trp level than in those with a high level (5-year OS 81.6% vs 93.8%; P = .019) ( Figure 1G ). Overall survival was also significantly poorer in patients with a high serum Kyn/Trp ratio than in those with a low ratio (5-year OS 60.0% vs 92.2%; P = .018) ( Figure 1H ).
In the present study, the cut-off value for serum sCD30 for OS was set at 285.6 ng/mL (Table S4 ). There was no significant difference in the OS between a high and a low serum sCD30 level (5-year OS 72.7% vs 94.4%; P = .125) ( Figure 2B ).
| Correlations of serum Kyn, Trp, the Kyn/Trp ratio, and sCD30 in HL patients
There was a significant positive correlation between serum Kyn and sCD30 (Rs = 0.535, P < .001; Figure 2C ) and a significant inverse correlation between Trp and sCD30 (Rs = À0.374, P = .006; Figure 2D ). There was also a significant positive correlation between the Kyn/Trp ratio and serum sCD30 concentration (Rs = 0.576, P < .001; Figure 2E ).
| Clinical characteristics of HL patients according to serum Kyn and Trp levels, and the Kyn/ Trp ratio
A high serum Kyn (>1.83 lmol/L) level was significantly associated with a low Hb level (P = .029), whereas a low serum Trp (≤57.1 lmol/L) was significantly associated with a low serum Alb (P = .038), as well as a low Hb level (P = .007), lymphocytopenia (P < .001), and a high serum sCD30 level (P = .027). Finally, a high serum Kyn/Trp ratio (>38.16) was significantly associated with a low
Hb level (P = .007), lymphocytopenia (P = .004), and a high serum sCD30 level (P = .003) ( Table 2 ).
3.8 | Progression-free survival and OS of HL patients according to component factors of IPS for advanced HL
There were no significant differences in either PFS or OS between older (≥45 years) and younger (<45 years) HL patients (P = .228 and P = .119, respectively). The PFS and OS rates at 5 years in the older HL patients were 76.1%, and 80.6%, respectively, and those in the younger patients 82.0% and 95.2%, respectively ( Figure S2a,b) . There
were also no significant differences in PFS in patients at Ann Arbor stage IV or stage I-III (P = .075); 5-year PFS in the former was 57.7% vs 84.9% in the latter ( Figure S2c ). However, OS was significantly shorter in stage IV patients than in stage I-III patients. Thus, the 5-year OS in the former was 78.8%, but 91.9% in the latter (P = .015) ( Figure S2d ). Neither were there any significant differences in PFS and OS between female and male HL patients (P = .954 and P = .394, respectively). The PFS and OS rates at 5 years in women were 78.6% and 95.0%, respectively, vs 79.9%
and 83.3%, respectively, in men ( Figure S2e,f) . There were also no significant differences in either PFS or OS between patients with a high or low Hb level (P = .377 and P = .131, respectively); 5-year PFS and OS in patients with a high Hb were 80.3%, and 91.1%, respectively, and those in patients with a low Hb were 72.9% and 71.4%, respectively ( Figure S2g,h) . Again, there were no significant differences in either PFS or OS between patients with high or low serum Alb levels (P = .440 and P = .547, respectively), the 5-year rates being 71.3% and 86.6%, respectively, in the high Alb group and 84.8% and 92.1%, respectively, in the low group ( Figure S2i,j) .
The same was true for patients with or without leukocytosis 
| DISCUSSION
It has been reported that, relative to healthy controls, serum Trp levels are significantly lower in several types of cancer such as colorectal cancer, 23 ovarian carcinoma, 24 and adult T-cell leukemia/lymphoma. 25 This might be due to accelerated Trp catabolism mediated by the IDO produced by tumor cells and/or non-tumor cells in the microenvironment. Consistent with these reports, we found that serum Trp levels were significantly lower in patients with HL than in healthy controls. In this context, the serum Kyn/Trp ratio was also higher in patients with HL than in healthy controls. It must be stated that, in the present study, serum Kyn and Trp levels and the Kyn/ Trp ratio in healthy controls were not identical with those of our previous study, 21 although the methods and the machine used (UPLC-MS/MS) were the same. Compared to the previous studies, some unavoidable variables, such as an error of calibration curve due to using different batches of reagents or components of the 16 Therefore, the serum Kyn/Trp ratio in patients with HL is likely to be dependent on IDO and probably not on tryptophan 2,3-dioxygenase or IDO2, produced by macrophages/dendritic cells in the tumor microenvironment.
In addition, interactions between colony stimulating factor-1 produced by HL tumor cells and the colony stimulating factor-1 receptor expressed by tumor-associated macrophages/dendritic cells should play an important role for the present observations. [31] [32] [33] Although the present study offers novel and important insights into the immunopathogenesis of HL, a significant limitation should also be borne in mind. The number of HL patients analyzed in the present study was relatively small, thus a definitive conclusion requires validation in another larger study. 
